Articles From: Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients to Keurig Green Mountain and Community Coffee Company Announce Partnership


Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today positive initial Phase 2 data with revusiran (ALN-TTRsc), an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR cardiac amyloidosis.
Sign-up for Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today six-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran (ALN-TTR02), an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP). These data are being presented at the American Neurological Association’s 2014 Annual Meeting being held October 12 – 14 in Baltimore.
Sign-up for Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP) investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated its DISCOVERY trial, a screening study examining the prevalence of transthyretin (TTR) mutations in patients suspected of having cardiac amyloidosis.
Sign-up for Alnylam Initiates DISCOVERY, a Screening Study Examining the Prevalence of Transthyretin (TTR) Mutations in Patients Suspected of Having Cardiac Amyloidosis investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the world’s leading acute/intensive care hospitals, announced today that Alnylam has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia.
Sign-up for Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has launched Alnylam Assist™, a program dedicated to providing support to patients, families, and caregivers.
Sign-up for Alnylam Launches Alnylam Assist™, Dedicated to Providing Support to Patients, Families, and Caregivers in Certain Genetic Diseases investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators from the American Porphyria Consortium and The European Porphyria Network have initiated the EXPLORE trial, a prospective observational study of patients with hepatic porphyrias, including Acute Intermittent Porphyria (AIP), Variegate Porphyria, and Hereditary Coproporphyria, suffering from recurrent attacks.
Sign-up for Alnylam Initiates EXPLORE, a Prospective Observational Study of Patients with Hepatic Porphyrias investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it presented new data from multiple clinical and pre-clinical studies at the 10 th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held October 12 – 15, 2014 in San Diego.
Sign-up for Alnylam Presents New Clinical and Pre-Clinical Data on RNAi Therapeutics at 10th Oligonucleotide Therapeutics Society (OTS) Meeting investment picks
Alnylam Pharmaceuticals, Inc .
Sign-up for Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has completed enrollment in its Phase 2 clinical trial with revusiran (re-VOO-si-ran), the recommended International Nonproprietary Name (INN) for ALN-TTRsc.
Sign-up for Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the appointment of Pushkal Garg, M.D., to the position of Senior Vice President, Clinical Development.
Sign-up for Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development investment picks
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic infectious disease pipeline.
Sign-up for Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases.
Sign-up for Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq: MDCO), a global biopharmaceutical company focused on hospital care, announced today that Alnylam has initiated a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia.
Sign-up for Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today its pipeline growth strategy for development and commercialization of RNAi therapeutics across three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic Infectious Disease.
Sign-up for Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or “STArs” investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today it has initiated the ENDEAVOUR Phase 3 clinical trial of revusiran in transthyretin (TTR)-mediated familial amyloidotic cardiomyopathy (FAC). FAC is one of the predominant clinical manifestations of TTR-mediated amyloidosis (ATTR), and afflicts an estimated 40,000 people worldwide.
Sign-up for Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of a peer-reviewed article in the Journal of the American Chemical Society describing the discovery of GalNAc-conjugated siRNA as a novel strategy for delivery of RNAi therapeutics.
Sign-up for New Paper in Journal of the American Chemical Society Documents Pioneering Discovery of GalNAc-Conjugated siRNA by Alnylam Scientists investment picks
2014/10/9
CA Technologies (NASDAQ: CA) and VersionOne today unveiled a PPM (Project & Portfolio Management) and Agile project management solution integration that gives technology leaders the insight to strategically plan, manage and track both Agile and waterfall project portfolios from concept to completion in a single console – making it easier to scale enterprise agility in lock step with traditional development and align with business objectives.
Sign-up for CA Technologies and VersionOne Partner on Integrated PPM and Agile Project Management investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982831001&sourceType=1 http://media3.marketwire.com/logos/20120223-PROPH.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Prophecy Provides Background on Pulacayo Property and Commences Evaluation of Historic Tailings investment picks
Integrated Device Technology, Inc. ( IDT ® ) (NASDAQ:IDTI) today expanded its VersaClock ® 5 family of low-power field-programmable clock generators with six new products that deliver industry-leading capabilities in multiple configurations to match varying application types.
Sign-up for IDT Expands VersaClock 5 Family with Six New Products, Delivering Best-in-Class Jitter Performance in Cost-Effective Configurations investment picks
Joint Innovation Delivers Reliable, Time-Saving External Storage Solutions and Online Collaboration Tools for the Pro Audio Workflow; Solutions Now Available at Sweetwater, Hal Leonard and Full Compass LOS ANGELES , Oct.
Sign-up for G-Technology® And Gobbler™ Form Strategic Alliance to Empower Audio Pros investment picks
Mobile Banking Company Monitise Taps IBM to Ensure Always on Business Operations RESEARCH TRIANGLE PARK, N.C. , Sept.
Sign-up for IBM Opens New Cloud Resiliency Center investment picks
8x8 offers one of the most comprehensive hosted communications feature sets that addresses the needs of a diverse customer audience MOUNTAIN VIEW, Calif.
Sign-up for Frost & Sullivan Commends 8x8's Success in Delivering Customer Value in the Cloud Communications and Contact Center Industry investment picks
FORT WASHINGTON, Pa., Dec.
Sign-up for Vitae Pharmaceuticals Among 2014 Best Places to Work in PA investment picks
Tyler Technologies, Inc. (NYSE: TYL) has signed a seven year software-as-a-service (SaaS) agreement with Altamonte Springs, Florida, for Tyler’s EnerGov ® planning, permitting and licensing and Munis ® enterprise resources planning (ERP) solutions to create efficiency by moving from about a dozen disparate systems to one integrated approach with Tyler.
Sign-up for Altamonte Springs, Florida, Signs SaaS Agreement for Tyler Technologies’ EnerGov and Munis Solutions investment picks
Global education leader Houghton Mifflin Harcourt (HMH) today announced Curious About Me for iPad®—an interactive story-building app that fosters language development skills and celebrates the curiosity and individuality of early learners.
Sign-up for Houghton Mifflin Harcourt Launches Curious About Me, a New Digital App Building Foundational Skills for Early Learners investment picks
2014/10/15
It’s no secret digital technology is taking over our lives, and face time with friends and loved ones is decreasing because of it.
Sign-up for New Survey Finds One-in-Four Americans Uses Digital Technology to Replace Face-to-Face Communication investment picks
Keurig Green Mountain, Inc., (Keurig) (NASDAQ: GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, today announced that Frances G.
Sign-up for Keurig Green Mountain Announces that Frances G. Rathke, Chief Financial Officer and Treasurer, will leave the Company in Fiscal Year 2015 investment picks
Keurig Green Mountain, Inc., (Keurig) (NASDAQ: GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, today announces that it is now the exclusive manufacturer of Meijer Brand K-Cup ® packs for the Keurig ® hot brewing system.
Sign-up for Keurig Green Mountain Welcomes Meijer K-Cup Packs into the Keurig Brewed Family investment picks
Keurig Green Mountain, Inc. (Keurig) (NASDAQ:GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, and Community Coffee Company, the largest family owned and operated retail coffee brand in America, announced a multi-year licensing, manufacturing, and distribution agreement to bring Community ® coffee to Keurig ® portion pack formats for consumer and commercial Keurig ® hot brewing systems.
Sign-up for Keurig Green Mountain and Community Coffee Company Announce Partnership investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients to Keurig Green Mountain and Community Coffee Company Announce Partnership
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent